Recent evidence highlights that sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as canagliflozin, attenuates VC in CKD rats by suppressing NLRP3-mediated cytokine release, suggesting a therapeutic avenue (59). The gene discussed is SLC5A2; the disease is chronic kidney disease.